Applied Therapeutics (NASDAQ:APLT - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.10 million for the quarter.
Applied Therapeutics Stock Performance
Shares of NASDAQ APLT traded down $0.01 during mid-day trading on Thursday, reaching $0.50. 1,988,069 shares of the company traded hands, compared to its average volume of 4,323,136. The stock has a market cap of $58.34 million, a PE ratio of -0.31 and a beta of 1.88. The company's fifty day moving average is $0.63 and its two-hundred day moving average is $4.43. Applied Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $10.62.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on APLT shares. Citigroup lowered their price objective on Applied Therapeutics from $13.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, November 29th. William Blair downgraded Applied Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, December 23rd. Robert W. Baird decreased their target price on Applied Therapeutics from $14.00 to $5.00 and set an "outperform" rating for the company in a research note on Friday, November 29th. Royal Bank of Canada decreased their target price on Applied Therapeutics from $4.00 to $1.50 and set a "sector perform" rating for the company in a research note on Friday, December 20th. Finally, UBS Group restated a "neutral" rating and set a $2.00 target price (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $6.10.
Read Our Latest Stock Analysis on APLT
About Applied Therapeutics
(
Get Free Report)
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
Recommended Stories
Before you consider Applied Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Applied Therapeutics wasn't on the list.
While Applied Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
